Novartis receives approval for Lucentis® and launches Galvus® in China, two innovative therapies
Novartis International AG / Novartis receives approval for Lucentis® and launches Galvus® in China, two innovative therapies that support public health goals . Processed and transmitted by Thomson Reuters ONE. The issuer is solely …